MYC and prostate cancer: Moreover, we found that 10058-F4, an inhibitor of c-Myc, decreases the viability of the enzalutamide-resistant LNCaP-ENR prostate cancer cells (Fig. 1F) which suggests that the ERPC cells are dependent on c-Myc for their survival and growth.